FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285275023> ?p ?o ?g. }

• W4285275023 endingPage "204512532211100" @default.
• W4285275023 startingPage "204512532211100" @default.
• W4285275023 abstract "The evidence for safe and effective interventions to treat the negative and cognitive symptoms of schizophrenia is lacking.Vortioxetine is a novel antidepressant that has been used as adjunctive therapy for the treatment of psychosis; however, its effectiveness in clinical practice is relatively unknown. In this study, we aimed to determine the potential clinical effectiveness and safety and tolerability of vortioxetine in psychosis.This is a non-interventional, retrospective study on the add-on use of vortioxetine in a group of people with schizophrenia-spectrum disorders in a large UK NHS mental health trust.Clinical effectiveness of vortioxetine was retrospectively assessed through the Clinical Global Impression - Severity (CGI-S) scale at 3 months. Safety and tolerability were evaluated through treatment discontinuation rates at 3, 6, and 12 months, and clinical reasons were evaluated at the primary endpoint of 3 months.Data were available for 40 subjects with a diagnosis of schizophrenia or schizoaffective disorder-prescribed vortioxetine treatment; 30 (75%) remained on treatment at 3 months. At CGI-S assessment, 15 of the 35 evaluated subjects reported at least a 1-point improvement, from 5 at baseline to 4 after 3 months of treatment. Twenty-six (65%) remained on treatment at 1-year follow-up. The main reasons for those discontinuing treatment were inadequate response (10%) and manic switch (7.5%), while one subject refused treatment. Tolerability to treatment was good, and 36 subjects (90%) reported no adverse events specific to vortioxetine treatment.Schizophrenia is a complex illness, and there is insufficient treatment response in many individuals. A significant proportion of whom may require adjunctive treatments depending on the nature of the residual symptoms. Vortioxetine could be a potentially safe and effective option in such people, but further controlled studies are required." @default.
• W4285275023 created "2022-07-14" @default.
• W4285275023 creator A5008873444 @default.
• W4285275023 creator A5024490730 @default.
• W4285275023 creator A5070414290 @default.
• W4285275023 creator A5075786466 @default.
• W4285275023 creator A5079077055 @default.
• W4285275023 creator A5081950728 @default.
• W4285275023 creator A5084477365 @default.
• W4285275023 creator A5088181811 @default.
• W4285275023 date "2022-01-01" @default.
• W4285275023 modified "2023-09-30" @default.
• W4285275023 title "Vortioxetine as adjunctive therapy in the treatment of schizophrenia" @default.
• W4285275023 cites W1487091206 @default.
• W4285275023 cites W1531015715 @default.
• W4285275023 cites W1967366594 @default.
• W4285275023 cites W1971360647 @default.
• W4285275023 cites W1983176528 @default.
• W4285275023 cites W2022707658 @default.
• W4285275023 cites W2040298842 @default.
• W4285275023 cites W2067098350 @default.
• W4285275023 cites W2094699069 @default.
• W4285275023 cites W2104255009 @default.
• W4285275023 cites W2115304718 @default.
• W4285275023 cites W2127888526 @default.
• W4285275023 cites W2129116806 @default.
• W4285275023 cites W2270496518 @default.
• W4285275023 cites W2290646566 @default.
• W4285275023 cites W2333551401 @default.
• W4285275023 cites W2419119392 @default.
• W4285275023 cites W2560754155 @default.
• W4285275023 cites W26981527 @default.
• W4285275023 cites W2742588837 @default.
• W4285275023 cites W2761471605 @default.
• W4285275023 cites W2765264947 @default.
• W4285275023 cites W3009591114 @default.
• W4285275023 cites W3038504360 @default.
• W4285275023 cites W3044680332 @default.
• W4285275023 cites W3107457431 @default.
• W4285275023 cites W3136671471 @default.
• W4285275023 cites W3183546267 @default.
• W4285275023 doi "https://doi.org/10.1177/20451253221110014" @default.
• W4285275023 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35833056" @default.
• W4285275023 hasPublicationYear "2022" @default.
• W4285275023 type Work @default.
• W4285275023 citedByCount "3" @default.
• W4285275023 countsByYear W42852750232022 @default.
• W4285275023 countsByYear W42852750232023 @default.
• W4285275023 crossrefType "journal-article" @default.
• W4285275023 hasAuthorship W4285275023A5008873444 @default.
• W4285275023 hasAuthorship W4285275023A5024490730 @default.
• W4285275023 hasAuthorship W4285275023A5070414290 @default.
• W4285275023 hasAuthorship W4285275023A5075786466 @default.
• W4285275023 hasAuthorship W4285275023A5079077055 @default.
• W4285275023 hasAuthorship W4285275023A5081950728 @default.
• W4285275023 hasAuthorship W4285275023A5084477365 @default.
• W4285275023 hasAuthorship W4285275023A5088181811 @default.
• W4285275023 hasBestOaLocation W42852750231 @default.
• W4285275023 hasConcept C118552586 @default.
• W4285275023 hasConcept C126322002 @default.
• W4285275023 hasConcept C142724271 @default.
• W4285275023 hasConcept C169900460 @default.
• W4285275023 hasConcept C197934379 @default.
• W4285275023 hasConcept C203092338 @default.
• W4285275023 hasConcept C204787440 @default.
• W4285275023 hasConcept C27081682 @default.
• W4285275023 hasConcept C2776000289 @default.
• W4285275023 hasConcept C2776412080 @default.
• W4285275023 hasConcept C2778034309 @default.
• W4285275023 hasConcept C2778375690 @default.
• W4285275023 hasConcept C2778715236 @default.
• W4285275023 hasConcept C2779727114 @default.
• W4285275023 hasConcept C2780051608 @default.
• W4285275023 hasConcept C2780325297 @default.
• W4285275023 hasConcept C3018162438 @default.
• W4285275023 hasConcept C535046627 @default.
• W4285275023 hasConcept C71924100 @default.
• W4285275023 hasConceptScore W4285275023C118552586 @default.
• W4285275023 hasConceptScore W4285275023C126322002 @default.
• W4285275023 hasConceptScore W4285275023C142724271 @default.
• W4285275023 hasConceptScore W4285275023C169900460 @default.
• W4285275023 hasConceptScore W4285275023C197934379 @default.
• W4285275023 hasConceptScore W4285275023C203092338 @default.
• W4285275023 hasConceptScore W4285275023C204787440 @default.
• W4285275023 hasConceptScore W4285275023C27081682 @default.
• W4285275023 hasConceptScore W4285275023C2776000289 @default.
• W4285275023 hasConceptScore W4285275023C2776412080 @default.
• W4285275023 hasConceptScore W4285275023C2778034309 @default.
• W4285275023 hasConceptScore W4285275023C2778375690 @default.
• W4285275023 hasConceptScore W4285275023C2778715236 @default.
• W4285275023 hasConceptScore W4285275023C2779727114 @default.
• W4285275023 hasConceptScore W4285275023C2780051608 @default.
• W4285275023 hasConceptScore W4285275023C2780325297 @default.
• W4285275023 hasConceptScore W4285275023C3018162438 @default.
• W4285275023 hasConceptScore W4285275023C535046627 @default.
• W4285275023 hasConceptScore W4285275023C71924100 @default.
• W4285275023 hasFunder F4320311196 @default.
• W4285275023 hasLocation W42852750231 @default.

• next